A randomized double-blind study of the effect of triiodothyronine on cardiac function and morbidity after coronary bypass surgery  by Mullis-Jansson, Samantha L. et al.
1128
actions of both triiodothyronine (T3) and tetraiodothy-
ronine (T4) on a variety of organ systems. These include
a decrease in peripheral vascular resistance and positive
chronotropic and inotropic effects.1-5
Several studies evaluating the impact of T3 adminis-
tration on low output states after cardiopulmonary
bypass have yielded conflicting data.6-9 The purpose of
our study was to re-examine the impact of intravenous
T3 administration on hemodynamic variables, inotropic
support requirements, and morbidity/mortality after
coronary artery bypass grafting (CABG).
Methods
After institutional review board approval and informed
written consent, patients undergoing CABG at Columbia-
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Background: Although triiodothyronine deficiency has been described
after cardiopulmonary bypass, data supporting its use have been con-
flicting. A double-blind, randomized, placebo-controlled study was
undertaken to further define the effect of triiodothyronine on hemody-
namics and outcome after coronary artery bypass grafting. Methods: A
total of 170 patients undergoing elective coronary artery bypass graft-
ing were enrolled and completed the study from November 1996
through March 1998. On removal of the aortic crossclamp, patients
were randomized to receive either intravenous triiodothyronine (0.4
m g/kg bolus plus 0.1 m g/kg infusion administered over a 6-hour period,
n = 81) or placebo (n = 89). Outcome variables included hemodynamic
profile and inotropic drug/pressor requirements at several time points
(mean ± standard error of the mean), perioperative morbidity (arrhyth-
mia/ischemia/infarction), and mortality. Results: Despite similar baseline
characteristics, patients randomized to triiodothyronine had a higher
cardiac index and lower inotropic requirements after the operation.
Subjects receiving triiodothyronine demonstrated a significantly lower
incidence of postoperative myocardial ischemia (4% vs 18%, P = .007)
and pacemaker dependence (14% vs 25%, P = .013). Seven patients in
the placebo group required postoperative mechanical assistance (intra-
aortic balloon pump, n = 4; left ventricular assist device, n = 3), com-
pared with none in the triiodothyronine group (P = .01). There were 2
deaths in the placebo group and no deaths in the triiodothyronine
group. Conclusions: Parenteral triiodothyronine given after crossclamp
removal during elective coronary artery bypass grafting significantly
improved postoperative ventricular function, reduced the need for treat-
ment with inotropic agents and mechanical devices, and decreased the
incidence of myocardial ischemia. The incidence of atrial fibrillation
was slightly decreased, and the need for postoperative pacemaker sup-
port was reduced. (J Thorac Cardiovasc Surg 1999;117:1128-35)
Samantha L. Mullis-Jansson, MDa
Michael Argenziano, MDb
Steven Corwin, MDc
Shunichi Homma, MDc
Alan D. Weinberg, MSb
Mat Williams, MDb
Eric A. Rose, MDb
Craig R. Smith, MDb
From the Departments of Anesthesiology,a Surgery,b and Medicine,c
Columbia University College of Physicians and Surgeons, New
York, NY.
Read at the Seventy-eighth Annual Meeting of The American
Association for Thoracic Surgery, Boston, Mass, May 3-6, 1998.
Received for publication May 8, 1998; revisions requested July 8,
1998; revisions received Feb 18, 1999; accepted for publication
Feb 19, 1999.
Address for reprints: Samantha L. Mullis-Jansson, MD, 177 Fort
Washington Ave, New York, NY 10032.
Copyright © 1999 by Mosby, Inc.
0022-5223/99 $8.00 + 0 12/6/98069
A RANDOMIZED DOUBLE-BLIND STUDY OF THE EFFECT OF TRIIODOTHYRONINE ON CARDIAC
FUNCTION AND MORBIDITY AFTER CORONARY BYPASS SURGERY
The Journal of Thoracic and
Cardiovascular Surgery
Volume 117, Number 6
Mullis-Jansson et al   1129
Presbyterian Medical Center were enrolled in a prospective,
double-blind, placebo-controlled trial over a 2-year period. A
total of 177 patients undergoing elective CABG were
enrolled from September 1996 through March 1998. The
nature of the operation between the 2 groups was as follows:
left internal thoracic artery, n = 145 (69 T3 and 76 placebo);
right internal thoracic artery, n = 1 (placebo); bilateral inter-
nal thoracic arteries, n = 20 (10 T3 and 10 placebo); and no
internal thoracic artery usage, n = 6 (4 T3 and 2 placebo). The
number of grafts per patient breaks down as follows: 1 vessel,
3 patients; 2 vessels, 32 patients; 3 vessels, 69 patients; 4 ves-
sels, 49 patients; 5 vessels, 19 patients; and 6 vessels, 1
patient. Exclusionary criteria included valvular surgery, his-
tory of thyroid disease or thyroid replacement therapy, evolv-
ing myocardial infarction, age greater than 85 years, preoper-
ative insertion of an intra-aortic balloon pump, and
emergency operation. Subjects were randomly assigned to 1
of 2 groups. The placebo and T3 groups were equally divided
among the surgeons participating in the study. Patients ran-
domized to the T3 group received T3 intravenously at the time
of aortic crossclamp removal (1 m g/kg bolus followed by 1
m g/kg infused over a 6-hour period), and those assigned to the
placebo group received an identical volume of normal saline
solution. There were no other differences in perioperative
treatment, and all staff involved in the care of the subjects
were blinded to subject assignment.
Outcome variables included perioperative hemodynamic
data, pressor and inotropic requirements, morbidity, and mor-
tality. Morbidity parameters included the prevalence of atrial
fibrillation, pacemaker dependence, myocardial ischemia and
infarction, and mechanical assistance (intra-aortic balloon
pump or left ventricular assist device). Pharmacologic and
hemodynamic data were collected before induction of anes-
thesia, on weaning from cardiopulmonary bypass, on arrival
in the intensive care unit (ICU), and at frequent subsequent
intervals until discharge from the ICU. Perioperative myocar-
dial ischemia/infarction was diagnosed electrocardiographi-
cally by an independent cardiologist, blinded to the protocol,
who applied creatine kinase MB fraction (>6%), aspartate
aminotransferase (>100 mg/dL), and electrocardiographic
criteria for myocardial infarction.
Preoperative and anesthetic management. Patients
receiving b -blockers or calcium channel blockers (or both)
received these medications on the morning of the operation.
Only patients who had been receiving stable dosages of these
medications for at least 2 weeks before the operation were
included in the study. Preoperative medication consisted of
midazolam 0.05 to 0.1 mg/kg orally in the preoperative hold-
ing area 1 hour before the operation. On arrival in the opera-
tive suite and before the induction of anesthesia, routine mon-
itoring was established, including placement of topical
electrocardiographic electrodes, radial artery and thermodilu-
tion catheters (Swan-Ganz catheters; Baxter Healthcare Corp,
Edwards Division, Santa Ana, Calif), and digital pulse oxime-
try. Hemodynamic monitoring included continuous measure-
ment of heart rate, arterial and central venous pressure, car-
diac output, and pulmonary artery pressure. Intravenous
induction was effected with fentanyl (25 m g/kg), midazolam
(0.05 mg/kg), and vecuronium (0.1 mg/kg). Inhalational
anesthetics were not used. Anesthesia was maintained with a
combination of intravenous fentanyl, midazolam, and vecuro-
nium by continuous infusion. Operating room data were con-
tinuously recorded by the LifeLog automated record keeper
(Modular Instruments, Malvern, Pa) and stored in a database
located in a central file server. Data from the ICU and cardiac
step-down units were collected on a portable computer and
analysis was performed off-line.
Statistical analysis. All data were analyzed with the use of
SAS system software (SAS Institute, Inc, Cary, NC). Data
were presented as mean ± standard deviation. Preliminarily,
continuous variables were compared by the paired and
unpaired Student t test and analysis of variance (ANOVA),
and discrete variables were analyzed by c 2 and Fisher’s exact
test.10-12
To discern whether a treatment effect existed postopera-
tively (myocardial ischemia/infarction, pacemaker depen-
dence, and atrial fibrillation), we used multiple logistic
regression, controlling for other preoperative and demo-
graphic variables, such as age, gender, ejection fraction, and
calcium channel and b -blockade. These equations also gener-
ate odds ratios and 95% confidence intervals. The longitudi-
nal data, such as heart rate, cardiac index, systemic vascular
resistance, and dopamine and dobutamine administration,
were studied with the use of a number of statistical methods:
repeated-measures ANOVA (Proc Mixed) to discern group
differences over time and Generalized Estimation Equations
(the GEE method) for incorporating covariates into the
model. Both methods allow for the covariance structure of the
data to be estimated, due to the potential correlation among
observations on the same individual between time points.
Results
Patient demographics. A total of 177 patients were
enrolled and randomized in the study. Two patients
were removed from the study at the discretion of the
attending cardiologist and 1 patient was excluded
because of massive hemorrhage in the immediate post-
operative period. Four patients were excluded on the
basis of incomplete data collection. In the final ana-
lyzed cohort of 170 patients, 81 were randomized to the
T3 group and 89 were assigned to the placebo group. As
summarized in Table I, the 2 groups were statistically
equivalent with respect to a variety of preoperative and
intraoperative factors, including medical and smoking
history, left ventricular ejection fraction, preoperative
medications, initial intraoperative hemodynamics, and
duration of cardiopulmonary bypass and aortic cross-
clamping. However, despite adequate randomization
with respect to these factors, patients in the placebo
group were an average of 4 years older than the patients
in the T3 group. Therefore, for all statistical analyses,
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age was adjusted for by multivariable techniques.
Hemodynamic effects. Before induction of anesthe-
sia, the T3 and placebo groups were similar with
respect to major hemodynamic indices, including heart
rate, cardiac index, pulmonary artery pressure, and sys-
temic vascular resistance. These parameters were eval-
uated subsequently after cardiopulmonary bypass, on
arrival in the ICU, and 6 and 12 hours after admission
to the ICU. By multivariable longitudinal analysis,
patients in the T3 group demonstrated a significantly
higher cardiac index than patients in the placebo group
in the 12 hours after cardiopulmonary bypass, with no
differences in heart rate, systemic vascular resistance,
or pulmonary artery pressure between groups in the
postoperative period (Table II).
Inotropic requirements. Postoperatively, require-
ments for inotropic support were recorded for 48 hours.
In the placebo group, 18% of patients were treated with
dopamine and 9% were receiving dobutamine on arrival
in the ICU, whereas only 11% and 5%, respectively, of
the patients in the T3 group were receiving these agents.
Inotropic requirements remained lower in the T3 group
than in the placebo group at all subsequent time points,
with significantly less dopamine dependence (P = .04)
and a trend toward less dobutamine dependence (P =
.07) by univariate longitudinal data analysis. Multi-
variate analysis of these data identified a number of inde-
pendent factors with influence on inotropic require-
ments, including age (P = .04 for dopamine and P =
.0001 for dobutamine), ejection fraction (P = .0007 for
dobutamine), and preoperative use of calcium chan-
nel–blocking agents (P = .02 for dopamine). After cor-
recting for these factors, patients in the T3 group had a
significantly decreased prevalence of dopamine adminis-
tration (P = .01) but no significant differences in dobut-
amine administration (P = .43) (Table III).
Table I. Patient demographics
Variable All patients T3 group Placebo group P value
n 170 81 89
Age (y) 64.1 ± 11.5 62.1 ± 12.5 66.0 ± 10.8 .03
Male 139 (81.2%) 65 (80.2%) 74 (83.1%) .77
Preoperative characteristics
Cigarettes 100 (58.1%) 49 (60.5%) 51 (57.3%) .79
Hypertension 97 (56.4%) 49 (60.5%) 48 (53.9%) .48
Preoperative MI 81 (47.1%) 36 (44.4%) 45 (50.6%) .52
b -Blockers 120 (69.8%) 54 (66.7%) 66 (74.2%) .37
Calcium channel blockers 58 (33.7%) 29 (35.8%) 29 (32.6%) .78
LV ejection fraction (%) 39.5 ± 13.2 39.2 ± 16.9 39.7 ± 15.9 .84
Intraoperative characteristics
CPB time (min) 103.9 ± 27.9 105.8 ± 28.5 102.1 ± 27.4 .39
Aortic crossclamp time (min) 69.0 ± 21.3 69.0 ± 23.2 69.0 ± 22.9 1.00
Induction HR 64 ± 13 63 ± 16 65 ± 15 .40
Induction CI 2.37 ± 0.64 2.43 ± 0.65 2.30 ± 0.63 .19
Induction PAD 15 ± 6 15 ± 9 16 ± 6 .39
Induction SVR 1605 ± 513 1567 ± 599 1645 ± 553 .38
MI, Myocardial infarction; LV, left ventricular; CPB, cardiopulmonary bypass; HR, heart rate; CI, cardiac index; PAD, pulmonary artery diastolic; SVR, systemic vas-
cular resistance.
Table II. Hemodynamic responses to T3 and placebo
Heart rate Cardiac index Systemic vascular resistance
Time point T3 Placebo T3 Placebo T3 Placebo
Before induction 63 ± 11 65 ± 14 2.43 ± 0.65 2.33 ± 0.58 1567 ± 472 1671 ± 517
After CPB 72 ± 14 76 ± 17 2.55 ± 0.57 2.16 ± 0.52 1139 ± 417 1458 ± 533
ICU arrival 76 ± 16 77 ± 17 2.27 ± 0.68 2.20 ± 0.65 1584 ± 638 1623 ± 677
Six hours 89 ± 17 88 ± 18 2.91 ± 0.65 2.63 ± 0.63 1069 ± 362 1129 ± 337
Twelve hours 90 ± 15 85 ± 15 3.01 ± 0.58 2.80 ± 0.64 1006 ± 345 1082 ± 273
P value* .69 .0001 .21
CPB, Cardiopulmonary bypass; ICU, intensive care unit.
*Multivariable longitudinal testing by repeated measures analysis (Generalized Estimating Equation, GEE) after adjusting for age and other covariates.
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Clinical outcome measures (morbidity and mor-
tality). Overall and group-specific morbidity and mor-
tality are detailed in Table IV. Overall, 19 patients
(11%) demonstrated evidence of perioperative myocar-
dial ischemia, and 11 of these (6.5%) met criteria for
myocardial infarction (8 transmural, 3 subendocardial).
Twenty-one patients (12%) had atrial fibrillation.
Independent predictors of myocardial ischemia includ-
ed preoperative calcium channel blocker therapy,
increasing cardiopulmonary bypass time, and random-
ization to the placebo group (Table V). Patients in the
T3 group had a 4% prevalence of myocardial ischemia,
which was significantly lower than the 18% noted in
the placebo group (P = .0019). Although the small
number of infarctions did not allow attainment of sta-
tistical significance, the rate of this complication was
2.5% in the T3 group as compared with 10.1% in the
placebo group. Atrial fibrillation was as frequent in the
T3 group (12.3%) as in the placebo group (12.4%), but
the prevalence of this complication increased with age
and was significantly lower in patients receiving b -
blocker therapy (Table V). Temporary or permanent
pacemaker support was required in a greater proportion
of patients in the placebo group (24.7%) than in the T3
group (13.6%, P = .013) and was also more common
with increasing age and cardiopulmonary bypass time
(Table V). Furthermore, 7 patients (4.1%) in the place-
bo group required temporary mechanical assistance
after the operation (4 intra-aortic balloon pumps, 3 left
ventricular assist devices), whereas no patient in the T3
group required such assistance. Finally, there were 2
deaths in the entire cohort of patients, both occurring in
patients assigned to the placebo group.
Influence of preoperative b -blocker therapy. The
effect of T3 administration on perioperative cardiac
index was most apparent in patients receiving b -block-
er agents before the operation. In these patients, T3
resulted in a progressive increase in cardiac index
beginning after cardiopulmonary bypass through 12
hours after ICU admission (Table VI). Systemic vascu-
lar resistance was similarly reduced after bypass in
patients receiving T3 as compared with those in the
placebo incidence cohort. Overall, b -blockade was
associated with a slightly lower prevalence of dopa-
mine and dobutamine administration. However, within
this group, T3 administration further lowered inotropic
use at all postoperative time points. Finally, the overall
incidence of perioperative myocardial ischemia (11%)
and the reduction in this incidence associated with T3
administration were no different in patients receiving
b -blockers than in the overall patient cohort. As noted
earlier, patients receiving preoperative b -blocking
agents had a significantly lower prevalence of atrial fib-
rillation, with no difference between those in the T3 and
placebo groups.
Effects of gender. Notably, the afore-described ben-
eficial effects of T3 on perioperative hemodynamics
were not observed in the female cohort of patients, in
whom there was no significant improvement in cardiac
index after T3 administration (Table VII). In fact, mul-
tivariate analysis revealed male gender as an indepen-
dent predictor of improved postoperative cardiac index
(data not shown). Nonetheless, the decrease in inotrop-
ic administration in women receiving T3 was of similar
magnitude to that of the total T3 cohort. Women receiv-
ing T3 also had a substantial reduction in incidence of
myocardial ischemia when compared with women
assigned to the placebo group.
Discussion
For more than a decade, the cardiovascular effects of
thyroid hormone have been investigated both in the lab-
oratory and in clinical trials. Initial results in rodent
models of myocardial infarction and heart failure sug-
gested that administration of physiologic doses of T3
produced significant improvement in left ventricular
Table III. Postoperative inotropic administration in
T3 and placebo groups
Dopamine Dobutamine
Time point T3 Placebo T3 Placebo
ICU arrival 11.1 18.0 4.9 9.0
Six hours 7.4 18.0 6.2 14.6
Twelve hours 11.1 19.1 6.2 14.6
Twenty-four hours 4.9 15.7 3.7 11.2
P value* .01 .43
Values represent percentage of patients who received inotropic support.
*Using multivariable logistic regression/repeated-measures ANOVA.
Table IV. Postoperative morbidity and mortality in T3
and placebo groups
T3 Placebo P value*
Myocardial ischemia 3 (3.7%) 16 (18.0%) .0019
Myocardial infarction 2 (2.5%) 9 (10.1%) .06
Atrial fibrillation 10 (12.3%) 11 (12.4%) 1.00
Pacemaker dependence 11 (13.6%) 22 (24.7%) .0128
Mechanical assistance 0 (0%) 7 (7.9%) .01
IABP 0 (0%) 4 (4.5%)
LVAD 0 (0%) 3 (3.4%)
Death 0 (0%) 2 (2.2%) .23
IABP, Intra-aortic balloon pump; LVAD, left ventricular assist device.
*By multiple logistic regression, adjusting for other covariates.
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performance.13-15 Concurrently, Novitzky and col-
leagues16 reported that T3 exerted significant beneficial
effects when administered to pigs subjected to myocar-
dial ischemia and cardiopulmonary bypass. In subse-
quent years, other basic science and clinical investiga-
tions supported the premise that thyroid hormone
metabolism was altered in advanced heart failure and
that T3 administration improved myocardial perfor-
mance after cardioplegic arrest and ischemic injury.17-19
In one clinical study, T3 was found to decrease the
prevalence of atrial fibrillation after CABG surgery.22
Despite these encouraging results, other studies have
failed to demonstrate significant improvements in clini-
cal outcome indices in patients treated with T3.21,22 For
this reason, T3 has not become a routine component of
pharmacologic management of patients with heart fail-
ure or those undergoing cardiopulmonary bypass. In an
effort to reconcile the issues raised by these conflicting
reports, we performed a clinical trial designed to close-
ly examine the effect of T3 on both physiologic parame-
ters and clinically relevant outcome variables in patients
undergoing CABG.
In our study, patients receiving T3 on crossclamp
removal and for 6 subsequent hours demonstrated sig-
nificantly better myocardial function after the opera-
tion than patients receiving placebo, resulting in lesser
requirements for inotropic support. Interestingly, these
benefits were not diminished by preoperative b -block-
er therapy. Although preoperative b -blocker therapy
did not influence the overall prevalence of periopera-
tive myocardial ischemia, T3 administration dramati-
cally reduced the rate of this complication. This effect
on the prevalence of perioperative ischemia is consis-
tent with data obtained in animal models of myocardial
ischemia. The requirement for mechanical assistance,
an indicator of profound myocardial dysfunction, was
significantly reduced in patients receiving T3, under-
scoring the potential clinical utility of this agent.
Table V. Independent predictors of myocardial ischemia, atrial fibrillation, and pacemaker dependence*
Outcome variable Preoperative variable P value Odds ratio 95% CI 
Myocardial ischemia T3 group .0019 0.11 0.03-0.45
Calcium channel blocker therapy .0129 3.88 1.33-11.29
CPB time (per 30 minutes) .0292 1.87 1.07-3.29
Atrial fibrillation Age (per decade) .0046 2.14 1.26-3.61
b -Blocker therapy .0095 0.28 0.10-0.73
Pacemaker dependence T3 group .0128 0.35 0.16-0.80
Age (per decade) .0431 1.48 1.01-2.18
CPB time (per 30 minutes) .0303 1.59 1.04-2.43
CI, Confidence interval; CPB, cardiopulmonary bypass.
*By multivariable logistic regression analysis.
Table VI. Results in patients on preoperative b -blocker
therapy
T3 Placebo P value*
n 53 66
Cardiac index (L/min/m2) .0088
Induction 2.4 ± 0.6 2.3 ± 0.5
After CPB 2.6 ± 0.6 2.1 ± 0.5
Six hours 2.9 ± 0.6 2.6 ± 0.6
Twelve hours 3.1 ± 0.6 2.8 ± 0.7
Dopamine dependence (%) .0498
ICU arrival 9.3 16.7
Six hours 3.7 15.2
Twelve hours 9.3 13.6
Twenty-four hours 3.7 12.1
Myocardial ischemia (%) 3.7 16.7 .036
Atrial fibrillation (%) 5.6 9.1 .512
CPB, Cardiopulmonary bypass; ICU, Intensive care unit.
*Multivariable longitudinal testing by Generalized Estimating Equation
(GEE) after adjusting for age and other covariates.
Table VII. Results in female patients
T3 Placebo P value*
n 17 14
Cardiac index (L/min/m2) .0001
Induction 2.1 ± 0.6 2.4 ± 0.8
After CPB 2.2 ± 0.6 2.1 ± 0.5
Six hours 2.3 ± 0.4 2.7 ± 0.7
Twelve hours 2.7 ± 0.5 2.6 ± 0.5
Dopamine dependence (%) .42
ICU arrival 11.8 21.4
Six hours 11.8 28.6
Twelve hours 17.6 35.7
Twenty-four hours 11.8 28.6
Myocardial ischemia (%) 0.0 21.4 .07
Atrial fibrillation (%) 11.1 21.4 .631
CPB, Cardiopulmonary bypass; ICU, intensive care unit.
*Multivariable longitudinal testing by Generalized Estimating Equation
(GEE) after adjusting for age and other covariates.
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Notably, although the clinically relevant beneficial
effects of T3 administration on perioperative inotropic
support and myocardial infarction were experienced by
patients of both sexes, improvements in cardiac index
were not observed in women. An explanation for the
differences between the genders remains to be found.
Atrial fibrillation remains a common postoperative
complication in patients undergoing CABG surgery,
occurring in 5% to 40% of patients and contributing
significantly to length of hospital stay and costs.23 A
variety of factors have been identified as predictors of
perioperative atrial fibrillation: These include advanced
age, male gender, preoperative hypertension, the
requirement for intra-aortic balloon pump support,
postoperative pneumonia, and the need for extended
postoperative ventilatory support.24-26 Others have sug-
gested that the presence of significant disease in the
vessels supplying the sinoatrial and atrioventricular
nodes is a strong predictor of postoperative atrial
arrhythmias.27 In our study, although increased age
conferred a higher risk for postoperative atrial fibrilla-
tion, neither gender, cardiopulmonary bypass time, nor
T3 therapy appeared to affect the incidence of this
arrhythmia. Finally, in patients receiving T3, there was
a dramatic decrease in the need for postoperative pace-
maker support (13.6% vs 24.7%) during the first 48
hours after cardiopulmonary bypass, confirming clini-
cally the experimentally established chronotropic
effects of this agent. Of the 6 patients who eventually
required permanent pacemaker insertion, only 1 was a
member of the T3 group.
In conclusion, our single-center study has confirmed
the positive inotropic and chronotropic effects of T3
administered perioperatively in patients undergoing
CABG and has furthermore identified clinically rele-
vant benefits in these patients, including reduced rates
of myocardial ischemia, pacemaker dependence, and
mechanical assistance. Although female patients did
not have the same improvement in hemodynamic
indices after T3 administration as their male counter-
parts, they experienced similar reductions in postoper-
ative inotropic requirements and complication rates.
The mechanisms by which T3 exerts these beneficial
effects is currently a matter of speculation and warrants
a multicenter investigation to confirm that T3 treatment
reduces perioperative myocardial infarction, lessens the
need for mechanical support, and increases survival.
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Discussion
Dr Andrew S. Wechsler (Philadelphia, Pa) [comments
read by Dr Hartzell V. Schaff, Rochester, Minn]. Dr Wechsler
was unable to be here, but he did record his review of the
manuscript. His comments are as follows:
Decreased levels of serum T3 have been consistently
demonstrated after cardiopulmonary bypass. Depression of
T3 levels exceeds that predicted from hemodilution and car-
diopulmonary bypass and is added to the list of interventions
possibly associated with euthyroid-sick syndrome. 
Far more controversial is the question of whether restoring
the serum T3 levels to normal results in a hemodynamic
advantage. Novitzky and his colleagues have consistently
demonstrated an improved hemodynamic performance after
T3 administration, but a Duke study of 211 patients showed
minimal effects. Klemper studied T3 administration com-
pared with placebo in 142 patients and found mild hemody-
namic improvement but no change in important clinical out-
comes. Your study demonstrates a major hemodynamic and
survival effect. The effect is much stronger than those previ-
ously demonstrated and raises some interesting questions. Dr
Wechsler has 4 questions to which I will add 2.
1. Do you believe that the dose of 1 m g/kg as a bolus and
then over the next 6 hours differed significantly enough from
doses used in prior studies to account for your observations? 
2. Did you require specific objective hemodynamic indices
to be obtained before initiating the drug? Could the vasodila-
tor effect of T3 and the accompanying increased inotropic
therapy have increased the cardiac index to account for the
differences? 
3. Your statistical method used predominantly univariate
comparisons between significant end points. Do you think the
data would hold up if subjected to a logistic regression analy-
sis or multivariate analysis that would eliminate data points
that served as surrogates for one or another? 
4. I did not note in your table whether there was a signifi-
cant difference in patients being operated on under reopera-
tive conditions between the 2 groups. Was there a difference? 
I would like to add 2 questions to Dr Wechsler’s:
One point that stood out in your presentation was the large
difference in enzyme leak. Was there a difference in Q-wave
myocardial infarction between the 2 groups? If not, how do
you account for postoperative creatine kinase release? As I
understand your protocol, the drug is given after the cross-
clamp is removed. Do you hypothesize some protective
effect, perhaps an influence on reperfusion, that decreases
ischemic injury? 
Dr Mullis-Jansson. To answer the first question in rela-
tionship to the dosage of the T3: dosages that had been given
in the past ranged from approximately 0.4 µg/kg all the way
up to 2 to 3 µg/kg, given as a bolus. In the groups that had the
2- to 3-µg/kg boluses, there were difficulties in terms of
maintaining pressure in relationship to vasodilatory respons-
es. Klemper’s group used a 0.8-µg/kg bolus. I do not think the
0.2-µg/kg difference between our study and Klemper’s study
would account for the difference in the results of the study.
One explanation for the difference in the result may be in
relationship to the percentage of patients in Klemper’s study
who had preoperative left ventricular dysfunction. We had a
higher percentage of patients with ejection fractions less than
40% than did Klemper. About 45% of our patients had an
ejection fraction less than 40%, and that may indeed explain
that there may be a selective beneficial effect in patients with
more morbid preoperative left ventricular function than the
patients with normal left ventricular function. 
Dr Schaff. The second question was whether the differ-
ences in hemodynamics might be accounted for by vasodi-
latation caused by the T3 and in subsequent inotropic use to
make up for that decrease in peripheral vascular resistance.
Dr Mullis-Jansson. We certainly did not see that. In fact,
the only end point in which we saw a statistical difference in
systemic vascular resistance was at the immediate postpul-
monary/cardiopulmonary bypass measurement. In all subse-
quent measurements there was no difference between the
groups, so I do not believe this is an afterload-reducing effect. 
Dr Schaff. What about the difference in creatine kinase
release? Is there a myocardial protective effect when the drug
is given after the crossclamp release?
Dr Mullis-Jansson. I cannot explain it. The diagnosis of
myocardial infarction was made by a cardiologist who was
blinded to the protocol. The cardiologist was given the data in
terms of each of the patients, and that included 5 days of elec-
trocardiograms and all the enzyme data that were obtained on
the patients for 3 days after the operation. The diagnosis was
made on that basis.
Dr Karl H. Krieger (New York, NY). One further question.
Atrial fibrillation is a major problem after CABG surgery,
particularly when considering length of stay. Dr Klemper’s
study noted a statistically significant decrease in atrial fibril-
lation; his rate, I think, was cut in half in patients who
received T3. In your study you showed a decreased incidence,
corroborating his study, but the difference did not reach sta-
tistical significance. Can you propose a mechanism by which
T3 would affect atrial fibrillation in the postoperative period?
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Dr Mullis-Jansson. In the animal model the beneficial
effects seem to be in relationship to decreasing the effects of
ischemia on sinoatrial and atrioventricular node function. In
the past, one of the proposed mechanisms for atrial fibrilla-
tion after CABG surgery has been to cause an insult to the
sinoatrial or atrioventricular node. Perhaps T3 in some way
protects this nodal mechanism such that the incidence of
postoperative arrhythmias will be lower.
Dr Ahmad Rajaii Khorasan (Neptune, NJ). The dramatic
difference in your survival results and the need for left ven-
tricular assist devices in the 2 groups raises a question about
the other important factors that can influence these outcomes:
for example, the extent of coronary disease, pump time, num-
ber of CABGs, and so on. Please comment on the distribution
of these variables in the 2 groups.
Dr Mullis-Jansson. In terms of those demographic para-
meters, the groups were equivalent. There was no difference
in the ischemic crossclamp time or cardiopulmonary bypass
time or in the number of grafts that were done. The patients
seemed to be equivalent in the 2 groups. We could find no dif-
ference. In fact, other papers have suggested that some of the
differences may be in relationship to those parameters, such
as preoperative incidence of hypertension or advanced age
(age is certainly a predictor of increased morbidity and mor-
tality). Our groups, however, were equivalent. 
Dr Patrick L. Ergina (Montreal, Quebec, Canada). I
have a question that was alluded to initially. I noticed that
you wanted to keep the mean arterial pressures fairly high.
When you treated those patients with pressors, which
many people believe have an inotropic effect to combat the
effect seen on your slide of decreased systemic vascular
resistance on the T3 group, did you look at that specifically
as a possible confounding variable? You used norepineph-
rine bitartrate (Levophed), but you did not document its
use.
Dr Mullis-Jansson. Right. We do use norepinephrine
bitartrate (Levophed), although that is not shown in our illus-
trations. The dosages of norepinephrine bitartrate (Levophed)
between the 2 groups were equivalent. 
Dr Ergina. My second question concerns pacing. Pacing
was more prevalent in the placebo group, and you noted that
there were more ischemic changes in 1 group. How did you
approach the paced electrocardiograms? 
Dr Mullis-Jansson. In this study there was only 1 patient
who was asystolic and in whom we could not get any type of
rhythm strip. In the other patients, the temporary pacemaker
was turned off before the 12-lead electrocardiogram was per-
formed, and then the cardiologist read the 12-lead electrocar-
diogram with the patient’s own native rhythm, albeit a slow
one. He read it from that rhythm and rate. 
